Avelox� Monotherapy Shows Strong Performance In Treating Hospitalized Pneumonia Patients Part 3

"Pneumonia is of selective exactness for the elderly and for population who suffer from hardened illnesses or who have an impair immune convention," explain Dr. Martin Springsklee, Vice President, Global Medical Affairs, Bayer Schering Pharma. "With Avelox, we submission an effective and certain treatment option, thus that patients may rest as hurriedly as viable from this unbearable corruption." About MOTIV The per protocol (PP) population of MOTIV consisted of 569 patients, 291 in the moxifloxacin and 278 in the comparator arm. Patients in the moxifloxacin arm received serialized intravenous (IV)/oral moxifloxacin 400mg once daily. Patients in the comparator arm received IV ceftriaxon 2g two times daily plus IV levofloxacin 500mg twice per sunshine and subsequently be switch to oral levofloxacin 500mg twice daily. Both group be treat for a pure of 7-14 days. At the test-of-cure estimation, in close proximity was no evocative departure in the clinical cure rates obtain with the two treatment (86.9% moxifloxacin group vs. 89.9% comparator group; 95% CI: -8.1-2.2%) irrespective of the graveness of pneumonia. Both regimen were well tolerated and there were no significant difference in the episode of adverse effects or mortality concerning both treatment artillery.

(8) i Finch R, Schurmann D, Collins O, et al.: A randomized controlled trial of serialized intravenous (i.v.) and oral moxifloxacin compare with sequential i.v. and oral co-amoxiclav with or in need clarithromycin in patients with syndicate acquire pneumonia require opening parenteral coverage. Antimicrob Agents Chemother 2002; 46:1746-1754 (9) Hoeffken G, Meyer HP, Winter J, Verhoef L; CAP Study Group: The efficacy and retreat of two oral moxifloxacin regimen compared to oral clarithromycin in the treatement of community-acquired pneumonia. Respir Med 2001; 95:553-64 (10) Torres A, Muir JF, Corris P, et al.: Effectiveness of oral moxifloxacin in common first-line analysis in community-acquired pneumonia. Eur Respir J 2003; 21:135-43 (11) Welte T, Petermann W, Schuermann D, Bauer TT, Reimnitz P; MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin be associated with faster clinical growth than was standard therapy in hospitalised patients with community-acquired pneumonia who received initial parenteral therapy. The MOXIRAPID Study Group. Clin Infect Dis 2005; 41:1697-705